GLP‑1 medicines have moved from metabolic workhorses to front-page news. Originally designed for diabetes, they now sit at the centre of conversations about obesity, cardiovascular risk – and increasingly, brain and cancer biology. Beneath the headlines, two distinct questions are emerging for R&D and portfolio leaders: In neurodegeneration, are GLP‑1s genuinely touching disease mechanisms in Alzheimer’s and Parkinson’s, or are they mainly cleaning up upstream metabolic and

Rare disease is no longer a niche topic — it has become a strategic priority for global commercial leaders and asset teams. As regulatory momentum builds and companies refine how they identify patients, generate evidence, and shape markets, rare disease is increasingly where scientific innovation and commercial differentiation meet.

For decades, families affected by rare diseases have heard the same heartbreaking message: ‘There is no approved treatment yet.’ In 2026, that story is finally changing. From the first-ever approval for Menkes disease to a landmark FDA policy shift for gene therapies, the rare disease landscape is transforming at a pace never seen before. Here’s what you need to know.

Ask any Specialty Pharma leader what they want in their next executive hire and you’ll hear familiar themes: “fresh thinking,” “diverse perspectives,” “ability to challenge the status quo.” Then the search progresses, and a strong candidate gets rejected with a vague line: “They’re great, but I’m not sure they’re a culture fit.” In many organizations, that is where diverse, high‑potential leaders—especially those who don’t look, talk, or network like the current C‑suite—qui